 |
185 Diseases |  |
81 Trials |
|
81 Trials |  |
6476 News |  |
| «12...70717273747576777879808182» |
- | levetiracetam / Generic mfg.
Enrollment closed, Enrollment change: NEOLEV2: Efficacy of Intravenous Levetiracetam in Neonatal Seizures (clinicaltrials.gov) - Nov 15, 2018
P1/2, N=280, Active, not recruiting, Sponsor: Richard H. Haas
Recruiting --> Active, not recruiting | N=100 --> 280
- || Aptiom (eslicarbazepine) / Sumitomo Pharma, BIAL
Enrollment closed, Trial completion date, Trial primary completion date, Monotherapy: A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures (clinicaltrials.gov) - Nov 14, 2018
P4, N=190, Active, not recruiting, Sponsor: Sunovion
Recruiting --> Active, not recruiting | N=100 --> 280 Recruiting --> Active, not recruiting | Trial completion date: Sep 2019 --> Feb 2019 | Trial primary completion date: Sep 2019 --> Feb 2019
- | lacosamide / Generic mfg., levetiracetam / Generic mfg.
Trial completion date, Trial initiation date, Trial primary completion date: Seizure Prophylaxis in Patients With Glioma or Brain Metastasis (clinicaltrials.gov) - Nov 8, 2018
P2, N=232, Not yet recruiting, Sponsor: Duke University
Recruiting --> Active, not recruiting | Trial completion date: Sep 2019 --> Feb 2019 | Trial primary completion date: Sep 2019 --> Feb 2019 Trial completion date: Sep 2020 --> Jan 2021 | Initiation date: Aug 2018 --> Dec 2018 | Trial primary completion date: Sep 2020 --> Jan 2021
- | NN1213 / Novo Nordisk
Trial completion, Adverse events: BEEP2b: Characterization of Epilepsy Patients BEEP 2b (clinicaltrials.gov) - Oct 23, 2018
P4, N=17, Completed, Sponsor: Food and Drug Administration (FDA)
Trial completion date: Sep 2020 --> Jan 2021 | Initiation date: Aug 2018 --> Dec 2018 | Trial primary completion date: Sep 2020 --> Jan 2021 Active, not recruiting --> Completed
- | levetiracetam / Generic mfg.
Trial initiation date: ILiAD: An Investigation of Levetiracetam in Alzheimer's Disease (clinicaltrials.gov) - Oct 16, 2018
P2, N=30, Enrolling by invitation, Sponsor: University of Oxford
Active, not recruiting --> Completed Initiation date: Apr 2018 --> Nov 2018
- | Actemra IV (tocilizumab) / Roche, JW Pharma, Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Kineret (anakinra) / SOBI
Enrollment open: Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants (clinicaltrials.gov) - Oct 10, 2018
P=N/A, N=500, Recruiting, Sponsor: Kevin Watt
Initiation date: Apr 2018 --> Nov 2018 Not yet recruiting --> Recruiting
- | padsevonil (UCB0942) / UCB
New P1 trial: A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on Padsevonil (clinicaltrials.gov) - Oct 2, 2018
P1, N=28, Recruiting, Sponsor: UCB Biopharma S.P.R.L.
- | levetiracetam / Generic mfg.
Clinical, Journal: Glioma-related seizures in relation to histopathological subtypes: a report from the glioma international case-control study. (Pubmed Central) - Sep 29, 2018
Gross total resection was associated with lower seizure frequency. Additionally, having a history of childhood seizures is not a risk factor ***for developing glioma-related seizures or glioma.
- | levetiracetam / Generic mfg.
Enrollment open: Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia (clinicaltrials.gov) - Sep 6, 2018
P=N/A, N=50, Recruiting, Sponsor: VA Office of Research and Development
Additionally, having a history of childhood seizures is not a risk factor ***for developing glioma-related seizures or glioma. Not yet recruiting --> Recruiting
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial primary completion date: Non-Myeloablative Bone Marrow Transplant for Patients With Sickle Cell Anemia and Other Blood Disorders (clinicaltrials.gov) - Aug 21, 2018
P2, N=43, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Not yet recruiting --> Recruiting Trial primary completion date: May 2018 --> Dec 2018
- | New P4 trial: PADRE: Pharmacokinetics of Antiepileptics in Patients on CRRT (clinicaltrials.gov) - Aug 16, 2018
P4, N=30, Recruiting, Sponsor: University of Maryland
- | levetiracetam / Generic mfg.
Trial completion date, Trial primary completion date: Levetiracetam (Keppra) to Improve Chronic Aphasia in Post-stroke Patients. (clinicaltrials.gov) - Aug 8, 2018
P1, N=50, Active, not recruiting, Sponsor: Kessler Foundation
Trial primary completion date: May 2018 --> Dec 2018 Trial completion date: Dec 2016 --> Dec 2019 | Trial primary completion date: Jun 2016 --> Dec 2019
- | levetiracetam / Generic mfg.
Trial completion: Cognitive Effects of Treatment of Interictal Discharges (clinicaltrials.gov) - Aug 7, 2018
P=N/A, N=31, Completed, Sponsor: Massachusetts General Hospital
Trial completion date: Dec 2016 --> Dec 2019 | Trial primary completion date: Jun 2016 --> Dec 2019 Recruiting --> Completed
- | lacosamide / Generic mfg., levetiracetam / Generic mfg.
Enrollment change: Seizure Prophylaxis in Patients With Glioma or Brain Metastasis (clinicaltrials.gov) - Aug 1, 2018
P2, N=232, Not yet recruiting, Sponsor: Duke University
Recruiting --> Completed N=116 --> 232
- | levetiracetam / Generic mfg.
Enrollment open: LEV-AD: Levetiracetam for Alzheimer's Disease-Associated Network Hyperexcitability (clinicaltrials.gov) - Jul 19, 2018
P2a, N=36, Recruiting, Sponsor: University of Minnesota - Clinical and Translational Science Institute
N=116 --> 232 Active, not recruiting --> Recruiting
- ||| Actemra IV (tocilizumab) / Roche, JW Pharma, Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Kineret (anakinra) / SOBI
New trial: Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants (clinicaltrials.gov) - Jul 15, 2018
P=N/A, N=500, Not yet recruiting, Sponsor: Kevin Watt
- | fludarabine IV / Generic mfg., busulfan / Generic mfg., levetiracetam / Generic mfg.
Trial completion date, Trial primary completion date: Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC) (clinicaltrials.gov) - Jul 13, 2018
P=N/A, N=30, Recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Active, not recruiting --> Recruiting Trial completion date: Jun 2018 --> Jun 2019 | Trial primary completion date: Jun 2018 --> Jun 2019
- | brivaracetam / Generic mfg.
Phase classification, Adverse events: Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV) (clinicaltrials.gov) - Jul 11, 2018
P3b, N=29, Completed, Sponsor: UCB Pharma SA
Trial completion date: Jun 2018 --> Jun 2019 | Trial primary completion date: Jun 2018 --> Jun 2019 Phase classification: P3 --> P3b
- | levetiracetam low dose (AGB101) / AgeneBio
Trial completion date, Trial primary completion date: Effects of Low-dose Levetiracetam on Clinical Symptoms, Cognition and Hippocampal Hyperactivity in Schizophrenia (clinicaltrials.gov) - Jun 21, 2018
P=N/A, N=30, Recruiting, Sponsor: University of Colorado, Denver
Phase classification: P3 --> P3b Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019
- | levetiracetam / Generic mfg.
Trial completion date, Trial primary completion date: LEVNEONAT-1: Levetiracetam Treatment of Neonatal Seizures: Safety and Efficacy Phase II Study (clinicaltrials.gov) - Jun 12, 2018
P2, N=50, Recruiting, Sponsor: University Hospital, Tours
Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019 Trial completion date: Oct 2019 --> Mar 2020 | Trial primary completion date: Feb 2018 --> Mar 2020
- levetiracetam / Generic mfg.
Enrollment change, Trial withdrawal: Efficacy of Keppra in Acute Alcohol Related Seizure Control--A Pilot Study (clinicaltrials.gov) - Jun 6, 2018
P2, N=0, Withdrawn, Sponsor: Medical University of South Carolina
Trial completion date: Oct 2019 --> Mar 2020 | Trial primary completion date: Feb 2018 --> Mar 2020 N=20 --> 0 | Not yet recruiting --> Withdrawn
- | levetiracetam / Generic mfg.
Trial completion date: NEOLEV2: Efficacy of Intravenous Levetiracetam in Neonatal Seizures (clinicaltrials.gov) - Jun 6, 2018
P1/2, N=100, Recruiting, Sponsor: Richard H. Haas
N=20 --> 0 | Not yet recruiting --> Withdrawn Trial completion date: Sep 2017 --> Dec 2018
- |||| levetiracetam / Generic mfg., topiramate / Generic mfg.
Trial completion date, Trial primary completion date, Monotherapy: A Study to Investigate the Safety of the Drugs Topiramate and Levetiracetam in Treating Children Recently Diagnosed With Epilepsy (clinicaltrials.gov) - May 4, 2018
P3, N=282, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Sep 2017 --> Dec 2018 Trial completion date: Mar 2019 --> Nov 2021 | Trial primary completion date: Mar 2018 --> Nov 2021
- | levetiracetam / Generic mfg.
Phase classification: 1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients (clinicaltrials.gov) - May 4, 2018
P4, N=82, Recruiting, Sponsor: University of Florida
Trial completion date: Mar 2019 --> Nov 2021 | Trial primary completion date: Mar 2018 --> Nov 2021 Phase classification: P=N/A --> P4
- || Aptiom (eslicarbazepine) / Sumitomo Pharma, BIAL
Trial completion date, Trial primary completion date, Monotherapy: A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures (clinicaltrials.gov) - May 3, 2018
P4, N=190, Recruiting, Sponsor: Sunovion
Phase classification: P=N/A --> P4 Trial completion date: Feb 2019 --> Sep 2019 | Trial primary completion date: Feb 2019 --> Sep 2019
- | levetiracetam / Generic mfg.
Clinical, Journal: Incidence, Characteristics, and Implications of Seizures in Patients With Glioblastoma. (Pubmed Central) - Apr 24, 2018
Trial completion date: Feb 2019 --> Sep 2019 | Trial primary completion date: Feb 2019 --> Sep 2019 Seizures are common in patients with glioblastoma and, in contrast to earlier reports, are not associated with a statistically significant improvement in survival.
- | levetiracetam / Generic mfg., carbamazepine / Generic mfg., oxcarbazepine / Generic mfg.
New P4 trial: Electroclinical Effect of Steroid in Patients With Benign Childhood Epilepsy With Centrotemporal Spikes (clinicaltrials.gov) - Apr 6, 2018
P4, N=100, Not yet recruiting, Sponsor: Assiut University
- | levetiracetam / Generic mfg.
New P2 trial: ILiAD: An Investigation of Levetiracetam in Alzheimer's Disease (clinicaltrials.gov) - Apr 5, 2018
P2, N=30, Enrolling by invitation, Sponsor: University of Oxford
- | levetiracetam / Generic mfg.
Enrollment change: Keppra IV for the Treatment of Motor Fluctuations in Parkinson's Disease (clinicaltrials.gov) - Mar 23, 2018
P4, N=0, Withdrawn, Sponsor: University of South Florida
Seizures are common in patients with glioblastoma and, in contrast to earlier reports, are not associated with a statistically significant improvement in survival. N=20 --> 0
- | levetiracetam / Generic mfg.
Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date: STING: Seizure Treatment in Glioma (clinicaltrials.gov) - Mar 7, 2018
P4, N=120, Recruiting, Sponsor: Leiden University Medical Center
N=20 --> 0 Not yet recruiting --> Recruiting | Trial completion date: Jun 2021 --> Feb 2022 | Initiation date: Jun 2017 --> Feb 2018 | Trial primary completion date: Dec 2018 --> Feb 2021
- | levetiracetam / Generic mfg.
Trial completion date, Trial primary completion date: SPAR: Seizure Prophylaxis in Aneurysm Repair (clinicaltrials.gov) - Feb 27, 2018
P4, N=400, Recruiting, Sponsor: University of Michigan
Not yet recruiting --> Recruiting | Trial completion date: Jun 2021 --> Feb 2022 | Initiation date: Jun 2017 --> Feb 2018 | Trial primary completion date: Dec 2018 --> Feb 2021 Trial primary completion date: Feb 2018 --> Feb 2020 | Trial completion date: Feb 2018 --> Feb 2020
- | levetiracetam / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: Seizure Activity in Alzheimer's Disease (clinicaltrials.gov) - Feb 23, 2018
P=N/A, N=20, Completed, Sponsor: Beth Israel Deaconess Medical Center
Trial primary completion date: Feb 2018 --> Feb 2020 | Trial completion date: Feb 2018 --> Feb 2020 Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Jul 2017 | Trial completion date: Jun 2018 --> Jul 2017
- | lacosamide / Generic mfg., levetiracetam / Generic mfg.
New P2 trial: Seizure Prophylaxis in Patients With Glioma or Brain Metastasis (clinicaltrials.gov) - Feb 19, 2018
P2, N=116, Not yet recruiting, Sponsor: Duke University
- | levetiracetam / Generic mfg.
Enrollment open, Trial initiation date, Trial primary completion date: LEVNEONAT-1: Levetiracetam Treatment of Neonatal Seizures: Safety and Efficacy Phase II Study (clinicaltrials.gov) - Feb 8, 2018
P2, N=50, Recruiting, Sponsor: University Hospital, Tours
Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Jul 2017 | Trial completion date: Jun 2018 --> Jul 2017 Not yet recruiting --> Recruiting | Initiation date: Dec 2014 --> Oct 2017 | Trial primary completion date: Dec 2016 --> Feb 2018
- | levetiracetam / Generic mfg.
Enrollment open, Trial initiation date, Monotherapy: PEACH: A Study of Levetiracetam as Monotherapy or Adjunctive Treatment of Partial Seizures in Pediatric Epileptic Subjects Ranging From 1 Month to Less Than 4 Years of Age (clinicaltrials.gov) - Feb 8, 2018
P3, N=48, Recruiting, Sponsor: UCB Japan Co. Ltd.
Not yet recruiting --> Recruiting | Initiation date: Dec 2014 --> Oct 2017 | Trial primary completion date: Dec 2016 --> Feb 2018 Not yet recruiting --> Recruiting | Initiation date: Nov 2017 --> Nov 2017
- | levetiracetam / Generic mfg.
Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date: Levetiracetam in Early Psychosis (clinicaltrials.gov) - Feb 5, 2018
P2, N=32, Recruiting, Sponsor: New York University School of Medicine
Not yet recruiting --> Recruiting | Initiation date: Nov 2017 --> Nov 2017 Withdrawn --> Recruiting | Initiation date: Aug 2016 --> May 2017 | Trial primary completion date: Apr 2017 --> Feb 2019 | Trial completion date: May 2018 --> Feb 2019
- | levetiracetam / Generic mfg.
Trial completion, Enrollment change: DOPAST: Short Duration Levetiracetam to Extended Course for Seizure Prophylaxis After aSAH (clinicaltrials.gov) - Jan 31, 2018
P3, N=84, Completed, Sponsor: Washington University School of Medicine
Withdrawn --> Recruiting | Initiation date: Aug 2016 --> May 2017 | Trial primary completion date: Apr 2017 --> Feb 2019 | Trial completion date: May 2018 --> Feb 2019 Recruiting --> Completed | N=460 --> 84
- | levetiracetam / Generic mfg.
Enrollment closed, Trial primary completion date: LEV-AD: Levetiracetam for Alzheimer's Disease-Associated Network Hyperexcitability (clinicaltrials.gov) - Jan 31, 2018
P2a, N=36, Active, not recruiting, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Recruiting --> Completed | N=460 --> 84 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Dec 2019
- | levetiracetam / Generic mfg.
Trial initiation date: Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia (clinicaltrials.gov) - Jan 24, 2018
P=N/A, N=50, Not yet recruiting, Sponsor: VA Office of Research and Development
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Dec 2019 Initiation date: Oct 2017 --> Apr 2018
- | levetiracetam / Generic mfg.
Trial primary completion date: Effects of Augmented Renal Clearance on Pharmacokinetic and Pharmacodynamic Properties of Levetiracetam in Subarachnoid Hemorrhage (clinicaltrials.gov) - Jan 18, 2018
P=N/A, N=20, Recruiting, Sponsor: University of Colorado, Denver
Initiation date: Oct 2017 --> Apr 2018 Trial primary completion date: Dec 2017 --> Dec 2018
- | levetiracetam / Generic mfg.
Enrollment open, Trial initiation date: Does Short-Term Anti-Seizure Prophylaxis After Traumatic Brain Injury Decrease Seizure Rates? (clinicaltrials.gov) - Dec 20, 2017
P4, N=2300, Recruiting, Sponsor: Loyola University
Trial primary completion date: Dec 2017 --> Dec 2018 Not yet recruiting --> Recruiting | Initiation date: Apr 2017 --> Jul 2017
- | phenytoin / Generic mfg., levetiracetam / Generic mfg., fosphenytoin / Generic mfg.
New trial: Antiepileptic Drugs and Vascular Risk Markers (clinicaltrials.gov) - Dec 19, 2017
P=N/A, N=52, Terminated, Sponsor: Thomas Jefferson University
- ||| Yescarta (axicabtagene ciloleucel) / Gilead
Enrollment change, Trial primary completion date: ZUMA-1: Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma (clinicaltrials.gov) - Dec 14, 2017
P1/2, N=200, Recruiting, Sponsor: Kite Pharma, Inc.
Not yet recruiting --> Recruiting | Initiation date: Apr 2017 --> Jul 2017 N=142 --> 200 | Trial primary completion date: Mar 2017 --> Aug 2018
- | levetiracetam / Generic mfg.
Trial primary completion date: LEV-AD: Levetiracetam for Alzheimer's Disease-Associated Network Hyperexcitability (clinicaltrials.gov) - Nov 27, 2017
P2a, N=36, Recruiting, Sponsor: University of Minnesota - Clinical and Translational Science Institute
N=142 --> 200 | Trial primary completion date: Mar 2017 --> Aug 2018 Trial primary completion date: Jun 2017 --> Dec 2017
- | levetiracetam / Generic mfg.
Trial completion, Enrollment change: Imaging the Effect of Centrotemporal Spikes and Seizures on Language in Children (clinicaltrials.gov) - Nov 14, 2017
P1, N=108, Completed, Sponsor: Children's Hospital Medical Center, Cincinnati
Trial primary completion date: Jun 2017 --> Dec 2017 Active, not recruiting --> Completed | N=144 --> 108
- ||| levetiracetam / Generic mfg.
New P3 trial, Monotherapy: PEACH: A Study of Levetiracetam as Monotherapy or Adjunctive Treatment of Partial Seizures in Pediatric Epileptic Subjects Ranging From 1 Month to Less Than 4 Years of Age (clinicaltrials.gov) - Nov 13, 2017
P3, N=48, Not yet recruiting, Sponsor: UCB Japan Co. Ltd.
- | levetiracetam / Generic mfg.
Enrollment change, Trial initiation date, Trial primary completion date: SPLASH - Pilot: Seizure Prophylaxis With Levetiracetam in Aneurysmal Subarachnoid Hemorrhage - Pilot Study (clinicaltrials.gov) - Nov 1, 2017
P4, N=0, Withdrawn, Sponsor: Vanderbilt University Medical Center
Active, not recruiting --> Completed | N=144 --> 108 N=36 --> 0 | Initiation date: Jan 2014 --> May 2013 | Trial primary completion date: Sep 2014 --> May 2013
- | brivaracetam / Generic mfg.
Trial completion, Trial primary completion date: A Brain Imaging Study With Positron Emission Tomography and the Radiotracer [11C]UCB-J to Estimate How Fast Brivaracetam and Levetiracetam Enter the Brain in Healthy Volunteers (clinicaltrials.gov) - Oct 30, 2017
P1, N=13, Completed, Sponsor: UCB Pharma
N=36 --> 0 | Initiation date: Jan 2014 --> May 2013 | Trial primary completion date: Sep 2014 --> May 2013 Recruiting --> Completed | Trial primary completion date: Jun 2017 --> Sep 2017
- | fludarabine IV / Generic mfg., busulfan / Generic mfg., levetiracetam / Generic mfg.
Trial primary completion date: Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC) (clinicaltrials.gov) - Oct 25, 2017
P=N/A, N=30, Recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Recruiting --> Completed | Trial primary completion date: Jun 2017 --> Sep 2017 Trial primary completion date: Jun 2017 --> Jun 2018
- | Enrollment change, Trial termination, Trial primary completion date, Adverse events: Pharmacovigilance in Gerontopsychiatric Patients (clinicaltrials.gov) - Oct 19, 2017
P3, N=407, Terminated, Sponsor: Hannover Medical School
Trial primary completion date: Jun 2017 --> Jun 2018 N=2000 --> 407 | Recruiting --> Terminated | Trial primary completion date: Feb 2017 --> Jun 2017